Onconova Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.01
Dividend & YieldN/A$ (N/A)
Beta 1.4
Market capitalization 17.11M
Operating cash flow -16.68M
ESG Scores unknown

Company description

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -1.85M 5k 336k -2.3M
Total Cashflows From Investing Activities -55k -55k -15k
Net Borrowings
Total Cash From Financing Activities 35.66M 26.65M 19.36M 55.56M
Change To Operating Activities 761k -269k 1.09M -1.3M
Issuance Of Stock 35.66M 26.65M 19.36M 55.56M
Net Income -20.57M -21.5M -25.16M -16.16M
Change In Cash 12.95M 5.76M -3.7M 36.05M
Effect Of Exchange Rate -15k -6k 32k -28k
Total Cash From Operating Activities -22.7M -20.83M -23.07M -19.49M
Depreciation 55k 14k 13k 14k
Change To Account Receivables 24k -63k 61k 9k
Other Cashflows From Financing Activities
Change To Netincome -1.11M 985k 577k 255k
Capital Expenditures -55k -55k -15k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 16.92M 15.26M 16.9M 7.3M
Income Before Tax -20.53M -21.49M -25.15M -16.16M
Net Income -20.57M -21.5M -25.16M -16.16M
Selling General Administrative 7.59M 6.78M 8.33M 9.43M
Gross Profit 1.23M 2.18M 231k 226k
Ebit -23.28M -19.86M -24.99M -16.5M
Operating Income -23.28M -19.86M -24.99M -16.5M
Interest Expense
Income Tax Expense -124k 10k 4k
Total Revenue 1.23M 2.18M 231k 226k
Cost Of Revenue
Total Other Income ExpenseNet 2.75M -1.64M -160k 333k
Net Income From Continuing Ops -20.41M -21.5M -25.16M -16.16M
Net Income Applicable To Common Shares -20.57M -21.5M -25.16M -16.16M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 12.54M 12.1M 13.81M 9.36M
Total Stockholder Equity 5.39M 11.57M 6.17M 46.12M
Other Current Liabilities 239k 226k 226k 226k
Total Assets 17.92M 23.67M 19.99M 55.48M
Common Stock 57k 1.11M 124k 209k
Other Current Assets 483k 461k 369k 50k
Retained Earnings -381.9M -403.4M -428.56M -444.72M
Treasury Stock -12k -18k 14k -14k
Cash 16.97M 22.73M 19.02M 55.07M
Total Current Liabilities 8.44M 8.29M 10.02M 6.12M
Other Stockholder Equity -12k -18k 14k -14k
Property, Plant, and Equipment 9k 50k 52k 38k
Total Current Assets 17.77M 23.47M 19.78M 55.43M
Net Tangible Assets 5.39M 11.57M 6.17M 46.12M
Net Receivables 35k 98k 37k 28k
Accounts Payable 4.04M 4.27M 4.83M 2.76M


Insider Transactions

Here are the insider transactions of stock shares related to Onconova Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HOFFMAN MICHAEL BSale at price 0.27 per share.D/I2020-08-27Director184.37k
REDDY E PREMKUMARSale at price 0.27 per share.D2020-08-27Director527.86k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 1.19 per share.I2019-09-24Beneficial Owner of more than 10% of a Class of Security16.7k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 1.23 - 1.62 per share.I2019-09-23Beneficial Owner of more than 10% of a Class of Security112.36k
ARMISTICE CAPITAL L.L.C.Sale at price 1.27 per share.I2019-09-23Beneficial Owner of more than 10% of a Class of Security10.25k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 2.10 per share.I2019-09-18Beneficial Owner of more than 10% of a Class of Security49.99k
683 CAPITAL MANAGEMENT L L CSale at price 1.76 - 1.86 per share.I2019-09-18Beneficial Owner of more than 10% of a Class of Security506.88k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 2.75 per share.I2019-09-11Beneficial Owner of more than 10% of a Class of Security1.25k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 2.77 per share.I2019-09-09Beneficial Owner of more than 10% of a Class of Security400
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 2.75 - 2.78 per share.I2019-09-06Beneficial Owner of more than 10% of a Class of Security5.42k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 2.81 - 2.83 per share.I2019-07-10Beneficial Owner of more than 10% of a Class of Security10.93k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 3.45 per share.I2019-06-27Beneficial Owner of more than 10% of a Class of Security1.46k
TYNDALL CAPITAL PARTNERS, L.P.Sale at price 3.40 per share.I2019-06-25Beneficial Owner of more than 10% of a Class of Security1.38k
HOFFMAN MICHAEL BSale at price 0.44 - 0.46 per share.I2018-08-29Director100k
TYNDALL CAPITAL PARTNERS, L.P.Stock Award(Grant) at price 2.10 per share.I2017-04-21Beneficial Owner of more than 10% of a Class of Security476.19k
MARINO JAMES JConversion of Exercise of derivative security at price 4.10 per share.D2016-08-01Director24.41k
BIENEN HENRY SConversion of Exercise of derivative security at price 4.10 per share.D2016-07-29Director7.42k
HOFFMAN MICHAEL BConversion of Exercise of derivative security at price 4.10 per share.I2016-07-29Director and Beneficial Owner of more than 10% of a Class of Security528.85k
KUMAR RAMESHConversion of Exercise of derivative security at price 4.10 per share.D2016-07-29Chief Executive Officer50.77k
REDDY E PREMKUMARConversion of Exercise of derivative security at price 4.10 per share.D2016-07-29Director133k
GUERIN MARK PATRICKConversion of Exercise of derivative security at price 4.10 per share.D2016-07-29Officer3.67k
FRUCHTMAN STEVEN MConversion of Exercise of derivative security at price 4.10 per share.D2016-07-29Officer6.28k
MANIAR MANOJ PH.D.Conversion of Exercise of derivative security at price 6.50 per share.D2016-06-30Officer50
GROOPMAN JEROME EConversion of Exercise of derivative security at price 5.20 per share.D2016-06-29Director10
MARINO JAMES JConversion of Exercise of derivative security at price 5.20 per share.D2016-06-27Director10
FRUCHTMAN STEVEN MConversion of Exercise of derivative security at price 6.50 per share.D2016-06-24Officer100
HOFFMAN MICHAEL BConversion of Exercise of derivative security at price 2.67 per share.D2014-07-07Director and Beneficial Owner of more than 10% of a Class of Security18.75k
REDDY E PREMKUMARConversion of Exercise of derivative security at price 1.33 per share.D2014-05-02Director27.08k
KUMAR RAMESHSale at price 15.02 - 15.11 per share.D2014-02-10Chief Executive Officer33.54k
KUMAR RAMESHConversion of Exercise of derivative security at price 6.00 per share.D2014-02-10Chief Executive Officer33.54k
KUMAR RAMESHSale at price 15.03 - 15.07 per share.D2014-02-03Chief Executive Officer60k
KUMAR RAMESHConversion of Exercise of derivative security at price 2.67 - 6.00 per share.D2014-02-03Chief Executive Officer60k
REDDY E PREMKUMARConversion of Exercise of derivative security at price 1.33 per share.D2013-12-19Director32.04k
ALTLAND JAMESConversion of Exercise of derivative security at price 6.00 per share.D2013-10-10Officer5k
MEHTA VIRENConversion of Exercise of derivative security at price 0.00 per share.D/I2013-07-30Director233.38k
BIENEN HENRY SConversion of Exercise of derivative security at price 0.00 per share.D2013-07-30Director6.87k
BANSAL AJAYConversion of Exercise of derivative security at price 0.00 per share.D2013-07-30Chief Financial Officer23.79k
HOFFMAN MICHAEL BConversion of Exercise of derivative security at price 0.00 per share.I2013-07-30Director and Beneficial Owner of more than 10% of a Class of Security2.73M
BAXTER HEALTHCARE SAConversion of Exercise of derivative security at price 0.00 per share.I2013-07-30Beneficial Owner of more than 10% of a Class of Security2.27M
MICHAEL & JANE HOFFMAN 2013 DESCENDANTSConversion of Exercise of derivative security at price 0.00 per share.D2013-07-30Beneficial Owner of more than 10% of a Class of Security2.64M
KUMAR RAMESHConversion of Exercise of derivative security at price 0.00 per share.D2013-07-30Chief Executive Officer25.79k
REDDY E PREMKUMARConversion of Exercise of derivative security at price 0.00 per share.D2013-07-30Director65.09k
ALTLAND JAMESConversion of Exercise of derivative security at price 6.00 per share.D2013-07-30Officer5k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Onconova Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Onconova Therapeutics Inc

Here is the result of two systematic investment strategies applied to Onconova Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Onconova Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Onconova Therapeutics Inc:

Onconova Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 365.46% on the backtest period.

Performance at glance

Performance

365.46 %

Latent gain

8237.78 $

Invested capital

2254.1 $

Annualized return

88.28 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Onconova Therapeutics Inc

This is the result of two momentum investment strategies applied to Onconova Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Onconova Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on Onconova Therapeutics Inc:

Onconova Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 470.64% of return on Onconova Therapeutics Inc. That represents 18859.22$ of latent gain with 4007.18$ of employed capital.
  • The second momentum investment strategy would give 357.51% of return on Onconova Therapeutics Inc. That represents 8056.54$ of latent gain with 2253.54$ of employed capital.
Performance at glance (1Q Momentum)

Performance

470.64 %

Latent gain

18859.22 $

Invested capital

4007.18 $

Annualized return

0.0 %
Performance at glance (2Q Momentum)

Performance

357.51 %

Latent gain

8056.54 $

Invested capital

2253.54 $

Annualized return

97.68 %

Momentum equity curve on Onconova Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to Onconova Therapeutics Inc:

Onconova Therapeutics Inc momentum equity

Note: the dividends potentially given by Onconova Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Onconova Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on Onconova Therapeutics Inc since the beginning:

Onconova Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Onconova Therapeutics Inc

Buy the dip entry openings on Onconova Therapeutics Inc

Onconova Therapeutics Inc

The performance achieved by the robo-advisor on Onconova Therapeutics Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Onconova Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Onconova Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

0.0 %

Equity curve of the strategy applied to Onconova Therapeutics Inc

The following chart shows the result of the investment strategy applied to Onconova Therapeutics Inc:

Onconova Therapeutics Inc

Note: the dividends potentially given by Onconova Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Onconova Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Onconova Therapeutics Inc:

Onconova Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Onconova Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to Onconova Therapeutics Inc.

Equity curve comparison on Onconova Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Onconova Therapeutics Inc investment strategy comparison

Employed capital comparison on Onconova Therapeutics Inc

Onconova Therapeutics Inc investment comparison

Performance comparison on Onconova Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 365.46% 8237.78$ 2254.1$ 88.28%
Momentum 1 quarter 470.64% 18859.22$ 4007.18$ 120.68%
Momentum 2 quarters 357.51% 8056.54$ 2253.54$ 97.68%
Non-directional 0% 0.0$ 0.0$ 0.0%
Annualized return comparison

Automatic investment

88.28 %

Momentum 1Q

97.68 %

Momentum 2Q

97.68 %

Non-directional

0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Onconova Therapeutics Inc:

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

  • AGROGENERATION

  • Note: The algorithm computes the probability of correlation between Onconova Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Onconova Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Onconova Therapeutics Inc
    Country United States
    City Newtown
    Address 12 Penns Trail
    Phone 267 759 3680
    Website www.onconova.com
    FullTime employees 14
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker ONTX
    Market www.nasdaq.com

    Onconova Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown